SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language
Search

CARDIOVASCULAR

International | eng
Country Language

Esprit™ BTK

Everolimus Eluting Resorbable Scaffold

Esprit BTK
Case Studies

Pioneering a new standard of care for BTK treatment.

The Esprit™ BTK System is the only BTK device that does it all for CLTI: delivers drug, provides support, and leaves nothing behind.1

48% Fewer Patients Require Reintervention2*

  • Patients with Esprit™ BTK System have 48% fewer reinterventions vs PTA at 2 years (9.7% vs 18.6%)
  • 90.3% of Esprit™ BTK patients did not require a reintervention through 2 years

Superior Efficacy, Sustained Benefits through 2 Years2,3

  • 31% improvement (74.5% vs. 43.7%) in limb salvage and primary patency at 1 year, with sustained benefits through 2 years
  • Demonstrated to be as safe as PTA at 2 years in the LIFE-BTK study

Proven Primary Treatment2

  • Addresses vessel recoil and dissection4, with radial strength similar to a metallic stent within the first 6 months5
  • Inhibits restenosis & maximizes patency through sustained everolimus elution6
  • Preserves flexibility for the future with complete resorption.1

How It Works

Watch how the Esprit™ BTK System can treat BTK (below-the-knee) lesions using a bioresorbable scaffold that addresses vessel recoil and dissection4, combined with a drug that inhibits neointimal hyperplasia6, and then fully resorbs over time1, preserving future treatment options.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • subtitles off, selected

      This device is commercially available for use in select international markets. Check the regulatory status in your geography.

      References

      *Reintervention defined as CD-TLR.

      1. Data on File. Excluding platinum markers
      2. Brian G. DeRubertis et al., Two-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions, VIVA 2024.
      3. Varcoe, RL., et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Eng J Med 2024;390:9-19.
      4. Esprit™ BTK Everolimus Eluting Resorbable Scaffold System Instructions for Use (IFU)
      5. Data on File. Testing done with XIENCE Sierra 3.5 x 38 mm at nominal.
      6. Data on File.

      MAT-2405960 v3.0

      POLICIES & ADVISORIES
      HEALTHCARE PROFESSIONALS
      PATIENTS & CAREGIVERS
      Abbott logo

      Information contained herein for distribution outside the U.S. only.

      CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

      Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

      Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

      © 2025 Abbott. All Rights Reserved.

      MAT-2001111 v8.0